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Abstract
Introduction. Thymectomy is a recommended treatment for myasthenia gravis, enfacing the problem of a low remission rate. However, Indonesian-specific
characteristics of myasthenia gravis are somehow different from those of well-developed countries. Thus, identifying prognostic factors influencing remission is required
for patient selection to provide optimal preoperative issues.
Methods. A retrospective cohort proceeded in our tertiary hospital, enrolling those diagnosed with myasthenia gravis who underwent thymectomy for four years. Disease
period modified Osserman classification, age, sex, preoperative plasmapheresis, preoperative steroid therapy, type of surgery, and thymic pathology were the variables
of interest for three-year follow-up. In addition, these variables were subjected to statistical analysis for prognostic factors.
Results. Twenty-six subjects completed the follow-up period with remission of 30.7% and associated with a period of suffering myasthenia gravis (p = 0.014) and the
modified Osserman classification (p = 0.008). The disease period showed a specificity of 88.9% with a negative predictive value of 84.2% and a sensitivity of 62.5%
with a positive predictive value of 71.4%. The modified Osserman classification showed a specificity of 83.2% with a negative predictive value of 88.2% and a sensitivity
of 75% with a positive predictive value of 66.7%).
Conclusions. In our tertiary hospital, the disease period and the modified Osserman classification are prognostic factors of remission following thymectomy for
myasthenia gravis.
Keywords: thymectomy, remission rate, modified Osserman classification

Introduction
Thymectomy is a recommended treatment in myasthenia gravis and
showed a five-year postoperative clinical remission rate of 45%, which
remains low (<50%).1 thus, identifying factors influencing the remission
after thymectomy is essential for patient selection to provide optimal
preoperative care.
A study by Amin in Indonesia reported that thymoma is one of the
causes of mortality in those with mediastinal mass (11.1%).2 Previous
studies showed eight identified prognostic factors for remission after
thymectomy: age, gender, disease period, modified Osserman
classification, preoperative plasmapheresis, preoperative steroid therapy,
type of surgery, and thymic pathology. However, one should note that
Indonesia has different characteristics than other studies in welldeveloped countries. Unfortunately, to date, no data on remission of
myasthenia gravis following thymectomy and its prognostic factor in
Indonesia. Thus, the study aimed to identify prognostic factors remission
after thymectomy for myasthenia gravis in our tertiary hospital, dr. Cipto
Mangunkusumo General Hospital (CMGH).
Method
The study proceeded retrospectively, enrolling patients who met the
criteria who underwent thymectomy for myasthenia gravis from
January 2014 to December 2018 who met the criteria. Those included
were patients with myasthenia gravis who experienced thymectomy and
had a three-year postoperative follow-up period. In contrast, those with
pregnancy and those with carcinoma were excluded. Data were
collected from medical records and reached out by telephone to find out
the information, including 1) ocular symptoms (double vision or weak
eyelids), bulbar symptoms (speech disability or swallowing disability),
leg muscle weakness, and shortness of breath, 2) myasthenia gravis
medication. These data were analyzed for sensitivity, specificity,
positive predictive value, negative predictive value, and likelihood ratio.

The committee of ethics, Faculty of Medicine, Universitas Indonesia,
approved the study (KET-890/UN2.F1/ETIK/PPM.00.02/2021)
and protocol number 21-07-0787).
Results
Thirty–two patients diagnosed with myasthenia gravis underwent a
thymectomy recorded. Out of this, 26 subjects with complete data were
included; the other six were excluded due to incomplete follow-up.
Subjects' characteristics are shown in Table 1.
Table 1. Subject characteristics
Variable
Age
<40 years
>40 years
Sex
Female
Male
Disease duration
<12 months
>12 months
Modified Osserman classification
Ocular weakness (I)
Mild general muscle weakness (II)
Moderate general muscle weakness (III)
Severe general muscle weakness (IV)
Respiratory insufficiency (V)
Preoperative plasmapheresis
Yes
No
Preoperative steroid therapy
Yes
No
Type of surgery
Sternotomy (transsternal)
Transcervical
VATS
Thymus histopathology
Thymic hyperplasia
Other

Frequency
38 + 15,6 years
14
12

Percentage (%)
N/A
53,8
46,2

18
8
21 (1-96) months
7
19

69,2
30,8
N/A
26,9
73,1

0
9
15
2
0

0
34,6
57,7
7,7
0

20
6

76,9
23,1

26
0

100
0

26
0
0

0
0
0

7
19

26,9
73,1
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The median age was 39.5 years (3–64 years), dominated by females
with disease periods varied from one to 96 months. Most of them had
modified Osserman classification category of class II (34.6%) and III
(57.7%), and no one with classes I and V. Most subjects received
preoperative plasmapheresis (100%). In addition, all subjects received
preoperative steroid therapy and underwent a sternotomy extended
thymectomy procedure (transsternal). Histopathological findings
showed thymoma in 14 subjects: 12 of class I and two of class II, and a
small number with thymic hyperplasia. Eight subjects (30.7%) had
remission, and the remaining 18 (69.3%) did not. Three subjects
(11.5%) with complete remission, five subjects (19.2%) with
pharmacological remission, and two subjects (7.7%) died.
The remission rate in those with a disease period <12 months was
71.4%, and the early modified Osserman classification was 66.7%. The
Fisher's test showed an association between the disease period with p–a
value of 0.014 and the modified Osserman classification with a p-value
of 0.008 with remission after thymectomy. The other factors, such as
age, gender, preoperative plasmapheresis, and histopathology findings,
showed a p-value of 1.0, 0.197, 0.628, and 1.0, respectively. No
statistical analysis proceeded on the type of surgery and preoperative
steroid therapy as all subjects underwent transsternal thymectomy
procedures and received preoperative steroid therapy (Table 2).
Table 2. Bivariate analysis of prognostic factors of myasthenia gravis remission after thymectomy
Variable
Age
− <40 years
− >40 years
Gender
− Female
− Male
Disease duration
− <12 months
− >12 months
Modified Osserman
classification
− I-II
− III-V
Preoperative
plasmapheresis
− Yes
− No
Thymus histopathology
− Thymic hyperplasia
− Other

Frequency

Remission
(%)

No remission
(%)

14
12

3 (21,4)
5 (41,7)

11 (78,6)
7 (58,3)

0,401

18
8

4 (22,2)
4 (50)

14 (77,8)
4 (50)

0,197

7
19

5 (71,4)
3 (15,8)

2 (28,6)
16 (84,2)

0,014**

9
17

6 (66,7)
2 (11,8)

3 (33,3)
15 (88,2)

0,008**

20
6

7 (35)
1 (16,7)

13 (65)
5 (83,3)

0,628

7
19

2 (28,6)
6 (31,6)

5 (71,4)
13 (68,4)

1,0

p*

In analyzing the prognostic factors (Table 3), the disease period showed
a specificity of 88.9% with a negative predictive value of 84.2%, a
likelihood ratio (+) of 5.6, and a likelihood ratio (-) of 0.42. The
sensitivity was 62.5%, with a positive predictive value of 71.4%. The
modified Osserman classification showed a specificity of 83.2%) with a
negative predictive value of 88.2%, a likelihood ratio (+) of 4.5, and a
likelihood ratio (-) of 0.3. The sensitivity was 75%, with a positive
predictive value of 66.7%.
Table 3. Sensitivity, specificity, positive predictive value, negative predictive value, and
likelihood ratio of prognostic factors of myasthenia gravis remission after thymectomy
Disease duration
Modified Osserman classification
Sensitivity (%)
62,5
75
Specificity (%)
88,9
83,3
PPV (%)
71,4
66,7
NPV (%)
84,2
88,2
LR (+)
5,6
4,5
LR (-)
0,42
0,3
Notes: PPV = Positive predictive value, NPN = Negative predictive value, LR = Likelihood ratio

Discussion
These study characteristics showed a broad age range from three to 64
years; three subjects of 3–15 years were recorded and found to be
paralleled to epidemiological data in Asia, showing those under 15 years

are common.3 In the study, 19 subjects (73.1%) showed a more extended
disease period (>12 months), and 17 subjects (65.4%) with the modified
Osserman classification categories III-V. These findings differed from
other studies abroad, showing a shorter disease period with a lower
modified Osserman classification (I-II) class.4,5 Our results showed that
remission remains low (<50%), which may be associated with our
subject's specific characteristics. This finding differed from other studies
showing an increasing remission rate with a longer follow-up to ten
years.6 Though some prognostic factors were identified, in this study,
only two variables described in the last paragraph showed to be
significant. The other factor showed no considerable correlation, age (p
= 0.401), and a difference from a previous study showing age is an
influencing factor for remission.7,8 The variation in age distribution and
other variables may contribute to confounding. However, in the study,
71.4% of those under 40 showed a longer disease period (>12 months).
The gender factor showed different findings from the previous study.
We found no association (p = 0.197) with remission after thymectomy,
which contradicts other studies showing female dominance.4,7 Subject
characteristics may contribute to the different findings; of female
subjects in the study, 61% showed advanced classification, and 66.7%
showed disease period >12 months.
The significant factor, namely, the disease period, showed an excellent
specificity of 88.9% with a negative predictive value of 84.2% and
moderate sensitivity of 62.5% with a positive predictive value of 71.4%,
referred to as a prognostic factor. Subjects with a disease period of <12
months showed a positive likelihood ratio of 5.6 and a negative
likelihood ratio of 0.3 in those of >12 months. A study showed remission
is higher in those with a shorter period between onset to the surgical
procedure (<8-12 months).7 Study by Iwasa showed a higher AchR
antibody in the longer period group than in the shorter duration.
Furthermore, a study showed that the antibody titers gradually decreased
from 6 months to >4 years postoperative.9 The finding is presumed to
explain higher remission rates after thymectomy in groups with shorter
disease periods.
The modified Osserman classification in the study showed a good
specificity of 83.2% with a negative predictive value of 88.2% and
moderate sensitivity of 75% with a positive predictive value of 66.7%,
referred to as a prognostic factor for remission after thymectomy. Those
in the lower category of the modified Osserman classification (class I-II)
showed a positive likelihood ratio of 4.5 and a negative likelihood ratio
of 0.3 for remission after thymectomy compared to the more advanced
category of the modified Osserman classification (class III-V). The
finding parallels a study that showed an association between AchR
antibody titer and the Osserman classification. Those with a lower
category of modified Osserman classification show low antibody titer
levels, whereas patients with advanced-category show higher antibody
levels.10 This might explain higher remission rates after thymectomy in
those with a lower category of the modified Osserman classification
group. In class I, those who underwent surgical procedures with six
months onset followed higher remission rates than those who did not.8
However, in this study, no subject with class I but advanced.
No association between plasmapheresis administration preoperatively in
our study with remission after thymectomy. A previous case series
showed a clinical improvement in their one-year postoperative
evaluation. They reported that three subjects experienced complete
remission, while two experienced clinical remission. However, in this
study, a low remission rate of 35% was found in subjects administered
with preoperative plasmapheresis. Our subject's characteristic – of > 12month disease period – may be responsible for the different findings.11
Preoperative steroid therapy was presumably associated with a higher
remission after thymectomy. Steroid inhibits the immune activation
process (T cell activation and B) cell proliferation which plays a role in
11
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subjects' autoimmune nature. The study compared those administered
with high-dose preoperative steroids for four to six weeks to those not
given.12 However, in this study, the subjects were those with category
class II-IV of modified Osserman classification class II-IV, thus,
receiving preoperative steroids. All subjects in this study proceeded with
an extended sternotomy transsternal thymectomy procedure.
Transcervical and VATS thymectomy have not been performed in
patients with myasthenia gravis in our center. In a recent study, thymic
hyperplasia on histopathology finding showed no association with
remission after thymectomy. It is because small subjects (26.9%)
showed thymic hyperplasia histopathology and found in contrast to
other studies showing most histopathology being thymic hyperplasia.5,4,8
This article is the first study focused on the prognostic factors of
remission after thymectomy for myasthenia gravis at the hospital.
Research power exceeding 80%, s study has an adequate sample,
including cases of myasthenia gravis who underwent thymectomy for
five years, with three years of postoperative follow-up. The finding may
be valuable as preliminary data for management and patient education.
For educational purposes, the result may be helpful to information not to
delay the surgical procedure. However, this study's limitation is a singlecenter referral with advanced characteristics. These characteristics may
contribute to low remission rates after thymectomy. In addition, the loss
to follow-up numbers in this study was relatively high (18.6%), despite
two variables (i.e., preoperative steroid therapy and type of surgical
procedure) being unable to be analyzed in this study since all subjects
received equal treatment.
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